Juneko Grilley-Olson, MD, Duke University, Durham, NC, discusses the promising results of the Phase II Alliance A091902 (NCT04339738) trial investigating the combination of cabozantinib and nivolumab for patients with locally advanced/metastatic angiosarcoma who had previously received taxane chemotherapy. The study enrolled patients who were not restricted on the number of prior lines but had not received prior anti-VEGF and immunotherapies. The combination therapy showed significant antitumor activity, with an objective response rate (ORR) of 62%, including responses in both cutaneous and noncutaneous disease subtypes. The treatment was well-tolerated without new safety concerns. The study highlights the potential of the cabozantinib and nivolumab combination in angiosarcoma subtypes, offering a new therapeutic option for patients with angiosarcoma pretreated with taxane. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
